Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

• Autor(es): Rose, Angela M. C. ; Pozo, Francisco ; Martínez‐Baz, Iván ; Mazagatos, Clara ; Bossuyt, Nathalie ; Cauchi, John Paul ; Petrović, Goranka ; Loghin, Isabela I. ; Vaikutyte, Roberta ; Buda, Silke ; Machado, Ausenda ; Duffy, Róisín ; Oroszi, Beatrix ; Howard, Jennifer ; Echeverria, Aitziber ; Andreu, Cristina ; Barbezange, Cyril ; Džiugytė, Aušra ; Nonković, Diana ; Popescu, Corneliu‐Petru ; Majauskaite, Fausta ; Tolksdorf, Kristin ; Gómez, Verónica ; Domegan, Lisa ; Horváth, Judit Krisztina ; Castilla, Jesús ; García, Miriam ; Demuyser, Thomas ; Borg, Maria‐Louise ; Tabain, Irena ; Lazar, Mihaela ; Kubiliute, Ieva ; Dürrwald, Ralf ; Guiomar, Raquel ; O'Donnell, Joan ; Kristóf, Katalin ; Nicolay, Nathalie ; Bacci, Sabrina ; Kissling, Esther ; VEBIS SARI VE network team ; Belgium SARI Surveillance Network (BelsariNet)
• Data: 2024
• Identificador Persistente: http://hdl.handle.net/10400.18/10326
• Origem: Repositório Científico do Instituto Nacional de Saúde
• Assunto(s): SARI Patients; Hospital; Influenza; Test-negative Design; Vaccine Effectiveness; Europe; Cuidados de Saúde; Vacina Gripe; Efetividade; VEBIS-LOT1
• Tipo de Documento: Artigo científico
• Idioma: Inglês
• Contribuidor(es): Repositório Científico do Instituto Nacional de Saúde

Descrição

We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (95% CI: −4–39) against A(H3N2) and 56% (95% CI: 22–75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.